SCHEMBL6087191

SCHEMBL6087191

Cc1cccc2oc(-c3c[nH]nc3-c3ccc(NC(=O)C4c5ccccc5-c5ccccc54)cc3)nc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CEPT1 Q9Y6K0 5/20 0.51
AGPAT2 O15120 2/20 0.46
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MAPT P10636 6/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
TP53 P04637 2/20 0.40
RXFP1 Q9HBX9 3/20 0.39
TOP2A P11388 2/20 0.39
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
P2RY1 P47900 1/20 0.36
CETP P11597 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085049 0.83 CETP (0.50) CEPT1AGPAT2NPC1RAB9AMAPT
SCHEMBL6086026 0.81 CEPT1 (0.47) CEPT1AGPAT2NPC1RAB9AMAPT
SCHEMBL6084017 0.81 CEPT1 (0.52) CEPT1AGPAT2NPC1RAB9AMAPT
SCHEMBL6085859 0.80 CEPT1 (0.51) CEPT1AGPAT2NPC1RAB9AMAPT
SCHEMBL6085513 0.79 CEPT1 (0.58) CEPT1AGPAT2MAPTSMN1; SMN2TP53
SCHEMBL6086552 0.79 CEPT1 (0.49) CEPT1AGPAT2NPC1RAB9AMAPT
SCHEMBL6085967 0.79 CEPT1 (0.51) CEPT1AGPAT2NPC1RAB9AMAPT
SCHEMBL6084212 0.79 CEPT1 (0.51) CEPT1AGPAT2NPC1RAB9AMAPT
SCHEMBL6086666 0.78 CEPT1 (0.49) CEPT1AGPAT2MAPTSMN1; SMN2TP53
SCHEMBL6085753 0.78 CEPT1 (0.55) CEPT1AGPAT2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 CEPT1 2798/4885AGPAT2 3284/4885NPC1 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.